OPRX-106

Protalix’ oral anti-TNF drug hits the mark in phase 2 ulcerative colitis trial
Fierce Biotech
Tue, 03/13/18 - 11:51 am
Protalix
anti-TNF
clinical trials
ulcerative colitis
OPRX-106